Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 4, 2013, Pages 291-301

  Morgan, Lisa A ^a   Olzinski, Alan R ^a   Upson, John J ^a   Zhao, Shufang ^b   Wang, Tao ^a   Eisennagel, Stephen H ^a   Hoang, Bao ^a   Tunstead, James R ^a   Marino, Joseph P ^a   Willette, Robert N ^a   Jucker, Beat M ^b   Behm, David J ^a  

^a GLAXOSMITHKLINE   (United States)

^b Laboratory Animal Sciences   (United States)

Author keywords

cardiac fibrosis; cardiac hypertrophy; diastolic dysfunction; soluble epoxide hydrolase; transverse aortic constriction

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GSK 2188931; GSK 2256294; HYDROLASE INHIBITOR; LEUKOTOXIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CARDIOVASCULAR FUNCTION; DRUG CONCENTRATION; ENZYME INHIBITION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA ANALYSIS; SYSTOLIC DYSFUNCTION;

ANIMALS; AORTA; CARDIOMEGALY; CONSTRICTION, PATHOLOGIC; CYCLOHEXYLAMINES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FIBROSIS; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TRIAZINES; VENTRICULAR REMODELING;

EID: 84876412416     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827fe59c     Document Type: Article

References (44)

1. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355: 260-269
2. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565-1574
3. Störk T, Möckel M, Danne O, et al. Left ventricular hypertrophy and diastolic dysfunction: Their relation to coronary heart disease. Cardiovasc Drugs Ther. 1995;9(suppl 3):533-537
4. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259
5. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992-998
6. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 2006; 103:18733-18738
7. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8: 794-805
8. Revermann M. Pharmacological inhibition of the soluble epoxide hydrolasefrom mouse to man. Curr Opin Pharmacol. 2010;10:173-178
9. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529-537
10. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006;99: 442-450
11. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemiareperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008;295: H2128-H2134
12. Nithipatikom K, Moore JM, Isbell MA, et al. Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;291:H537-H542
13. Gross GJ, Hsu A, Falck JR, et al. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol. 2007;42:687-691
14. Li N, Liu JY, Timofeyev V, et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J Mol Cell Cardiol. 2009;47:835-845
15. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009;106:564-569
16. Kompa AR, Wang BH, Xu G, et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. Int J Cardiol. In press
17. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39(pt 2):690-694
18. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:1244-1253
19. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in saltsensitive hypertension. Hypertension. 2005;46:975-981
20. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension. 2005;45: 759-765
21. Anandan SK, Webb HK, Chen D, et al. 1-(1-Acetyl-piperidin-4-yl)- 3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg Med Chem Lett. 2011;21: 983-988
22. Shen HC, Ding FX, Deng Q, et al. Discovery of 3,3-disubstituted piperidine- derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009;19:5314-5320
23. Shen HC, Ding FX, Wang S, et al. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009;19: 3398-3404
24. Huang D, Cheng JW. Pharmacologic management of heart failure with preserved ejection fraction. Ann Pharmacother. 2010;44:1933-1945
25. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108: 1429-1437
26. Moghaddam MF, Grant DF, Cheek JM, et al. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med. 1997;3: 562-566
27. Jones PD, Tsai HJ, Do ZN, et al. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006;16:5212-5216
28. Kim IH, Tsai HJ, Nishi K, et al. 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem. 2007;50: 5217-5226
29. Fang X, Hu S, Watanabe T, et al. Activation of peroxisome proliferatoractivated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005;314:260-270
30. Rohini A, Agrawal N, Koyani CN, et al. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 2010;61:269-280
31. Newman JW, Morisseau C, Harris TR, et al. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A. 2003;100: 1558-1563
32. Gross GJ, Nithipatikom K. Soluble epoxide hydrolase: A new target for cardioprotection. Curr Opin Investig Drugs. 2009;10:253-258
33. EnayetAllah AE, Luria A, Luo B, et al. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J Biol Chem. 2008;283:36592-36598
34. Rückle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: Towards an'aspirin of the 21st century'? Nat Rev Drug Discov. 2006;5:903-918
35. Sinal CJ, Miyata M, Tohkin M, et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504-40510
36. Luria A, Weldon SM, Kabcenell AK, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem. 2007;282:2891-2898
37. Reddy DS, Singh M, Ghosh S, et al. Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction. Mol Cell Biochem. 1996;155:1-11
38. Mukawa H, Toki Y, Miyazaki Y, et al. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res. 2003;26:89-95
39. Ago T, Yang Y, Zhai P, et al. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload. J Cardiovasc Transl Res. 2010;3:304-313
40. Li J, Carroll MA, Chander PN, et al. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci. 2008; 13:3480-3487
41. Iyer A, Kauter K, Alam MA, et al. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res. 2012;2012:758614
42. Loch D, Hoey A, Morisseau C, et al. Prevention of hypertension in DOCA salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007;47:87-98
43. Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol. 2007;43:388-403
44. Merabet N, Bellien J, Glevarec E, et al. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. J Mol Cell Cardiol. 2012;52:660-666